KIT and neoplasm: It inhibits three oncogenic pathways, specifically: (a) cell growth by inhibition of KIT, RET, RAF-1 and BRAF; (b) tumor angiogenesis by targeting vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3, and the tyrosine kinase with immunoglobulin and EGF homology domain 2 (TIE2); and (c) the tumor microenvironment by hampering fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor-b (PDGR-b) [267,268,269].